Clinical Study of Tirellizumab Combined with Chemotherapy in First-line Treatment of Advanced Non-small Cell Lung Cancer
Objective To investigate the clinical effect of Tirellizumab combined with first-line chemotherapy in pa-tients with advanced non-small cell lung cancer.Methods A total of 320 patients with advanced non-small cell lung cancer who received first-line chemotherapy in the Oncology Department of Binzhou Central Hospital from June 2020 to June 2023 were selected as the study objects,and were divided into control group(160 cases)and observation group(160 cases)by random number table method.The control group received PP(cisplatin+pemetrexed),GP(cisplatin+gemcitabine),NP(Cisplatin+vinorelbine)or TP(Cisplatin+paclitaxel)chemotherapy,and the observation group was combined with tirellizumab on the basis of the control group.After 3 treatment cycles,the short-term efficacy and tu-mor marker levels of the two groups were compared.Results The disease control rate and objective effective rate in the observation group were 88.13%and 63.75%,respectively,higher than 64.38%and 33.75%in the control group,and the diffrences were statistically significant(both P<0.05).After 3 cycles of chemotherapy,the levels of soluble fragments of cancer antigen 125,carcinoembryonic antigen,squamous cell carcinoma antigen and cytokeratin 19 frag-ment in observation group were lower than those in control group,and the diffrences were statistically significant(all P<0.05).Conclusion Reasonable application of Tirellizumab in first-line chemotherapy can effectively improve the short-term efficacy and significantly inhibit the level of tumor markers,which has clinical application value.
Middle and late stageNon-small cell lung cancerTirellizumabChemotherapy
NETL
NSTL
万方数据
